Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Emmanuel Antonarakis MD

Emmanuel S Antonarakis MD

Professor of Oncology and Urology, Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Dr Antonarakis is a Professor of Oncology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. He graduated from the University of Wales College of Medicine (United Kingdom) in 2003, and then completed a Residency in Internal Medicine at the Johns Hopkins Bayview Medical Center, followed by a Fellowship in Medical Oncology at the Johns Hopkins Hospital. In 2010, he joined the Johns Hopkins faculty as an attending physician and translational researcher. Dr Antonarakis’ clinical interest is the management of prostate cancer and other genitourinary malignancies (cancers of the bladder, kidney and testis).

His research focuses on drug development and clinical trial design for patients with prostate cancer. More specifically, he is interested in developing novel androgen-directed therapies as well as immunotherapies for men with recurrent or advanced prostate cancer. He also has an interest in biomarker development, specifically the clinical validation of the AR-V7 marker. He is currently the PI of several phase II and III prostate cancer trials, and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the Eastern Cooperative Oncology Group (ECOG) as well as the NCI Prostate Cancer Task Force and the NCCN Prostate Cancer Panel. He serves on the Editorial Board of several oncology journals, including the Journal of Clinical Oncology. He is the author of over 140 peer-reviewed articles, and several book chapters.


Dr. Antonarakis reports no disclosures.